Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRI-NORINYL 28-DAY vs TRI-LEGEST FE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also increases viscosity of cervical mucus and alters endometrial lining to reduce implantation likelihood.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by one placebo tablet orally once daily for 7 days. Each active tablet contains 0.035 mg ethinyl estradiol and 0.5 mg norethindrone (7 days), 0.035 mg ethinyl estradiol and 1.0 mg norethindrone (9 days), and 0.035 mg ethinyl estradiol and 0.5 mg norethindrone (5 days).
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
Ethinyl estradiol: 17 ± 6 hours (terminal); Norethindrone: 10 ± 3 hours (terminal). Steady-state achieved after 7-14 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Ethinyl estradiol primarily metabolized by CYP3A4 via hydroxylation. Norethindrone metabolized by CYP3A4 and CYP2C9. Both undergo conjugation (glucuronidation and sulfation).
No specific dose adjustment required based on GFR. Contraindicated in patients with acute or chronic hepatic dysfunction with impaired renal function.
No specific guidelines exist; use with caution in renal impairment due to potential for fluid retention and hyperkalemia.
Cigarette smoking increases the risk of serious cardiovascular adverse events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: no increased risk of major malformations from combination oral contraceptives in most studies, but post-marketing reports of fetal abnormalities. Second and third trimesters: associated with increased risk of fetal genital tract abnormalities (e.g., hypospadias, vaginal adenosis) and possible carcinogenic effects. Use during pregnancy is not recommended; discontinue if pregnancy occurs.
Pregnancy category X. Combination hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester use may cause small increased risk of limb reduction defects and cardiovascular anomalies; second and third trimester exposure is associated with masculinization of female fetuses due to progestin component. Discontinue immediately if pregnancy occurs.
TRI-NORINYL 28-DAY is a triphasic combined oral contraceptive containing norethindrone and ethinyl estradiol. The varying hormone doses across the 21-day active phase mimic the natural menstrual cycle, potentially reducing breakthrough bleeding. Initiate on the first day of menstrual period for immediate contraceptive effect; if starting on other days, use backup contraception for 7 days. Missed pill management: if one pill is missed, take it as soon as remembered, even if that means taking two pills in one day; if two or more pills are missed, use backup contraception for 7 days and consult package insert. Monitor for thromboembolic risk, especially in smokers over 35, hypertension, or migraine with aura. Counsel about breakthrough bleeding, which is common in the first few cycles.
Tri-Legest Fe is a combination oral contraceptive containing estradiol and norethindrone. Its 91-day extended-cycle regimen (84 active pills followed by 7 low-dose estrogen pills) reduces menstruation frequency to once every 3 months. Use caution in patients with migraine with aura, hypertension, or smoking over age 35 due to increased thromboembolic risk. The low-dose estrogen pills (10 mcg ethinyl estradiol) during week 13 help maintain hormone levels and reduce breakthrough bleeding. Advise patients to take at the same time daily; missed pills increase pregnancy risk.
No interactions on record
No interactions on record
TRI-NORINYL 28-DAY and TRI-LEGEST FE are distinct pharmacological agents. TRI-NORINYL 28-DAY belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyOral contraceptive. TRI-LEGEST FE belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRI-NORINYL 28-DAY carries a safety status of Category C, whereas TRI-LEGEST FE safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone acetate is hydrolyzed to norethindrone, which is metabolized by reduction and conjugation (glucuronidation and sulfation).
Renal: 40% as metabolites; Fecal: 50% as metabolites; Biliary: minor; unchanged ethinyl estradiol excreted in urine <5%, norethindrone <1%.
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Ethinyl estradiol: 97-98% (albumin 70%, SHBG 30%); Norethindrone: 95-99% (albumin 61%, SHBG 38%).
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: >95% bound to albumin.
Ethinyl estradiol: 2.7-3.1 L/kg; Norethindrone: 4.8-5.3 L/kg. Indicates extensive tissue distribution.
Norethindrone: 3-4 L/kg; Ethinyl estradiol: 2-3 L/kg. Indicates extensive tissue distribution.
Oral: Ethinyl estradiol 38-48% (first-pass metabolism); Norethindrone 64-65% (first-pass metabolism).
Oral: Norethindrone ~60% (first-pass metabolism); Ethinyl estradiol ~45-55% (first-pass and gut wall metabolism).
Contraindicated in patients with acute or chronic hepatic disease (Child-Pugh class B or C). For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment available.
Contraindicated in severe hepatic disease or active liver disease (Child-Pugh Class C). Use with caution in mild to moderate impairment (Child-Pugh A/B) without specific dose adjustment.
Not indicated for use before menarche. After menarche, standard adult dosing applies.
Not indicated in premenarchal females; after menarche, same dosing as adults but only for contraception after assessment of skeletal maturity.
Not indicated for use after menopause. No specific geriatric dose adjustment required if used off-label in perimenopausal women, but consider increased risk of cardiovascular events and venous thromboembolism.
Not indicated for use in postmenopausal women; no specific dose adjustments in elderly females of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with number of cigarettes smoked. Women over 35 who smoke should not use combination oral contraceptives.
Grapefruit juice may increase ethinyl estradiol levels by inhibiting CYP3A4, potentially increasing side effects. Avoid large quantities of grapefruit juice. No specific food restrictions. St. John's Wort, an herbal supplement, can reduce contraceptive efficacy. High-fat meals may slightly increase ethinyl estradiol absorption but not clinically significant.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol intake as it may impair liver metabolism and increase risk of breakthrough bleeding.
Small amounts of ethinyl estradiol and norethindrone excreted in breast milk. M/P ratio: ethinyl estradiol ~0.5; norethindrone ~0.6. May reduce milk production and quality. Use in breastfeeding is generally not recommended; alternative contraception advised for nursing mothers.
Small amounts of steroids pass into breast milk (M/P ratio unknown, estimated <1%). CHCs may reduce milk production and composition, especially with early postpartum use. Avoid use during lactation; progestin-only methods preferred. Use only if benefits outweigh risks.
Contraindicated in pregnancy; no dosing adjustments are applicable. If pregnancy occurs, discontinue immediately. Pharmacokinetic changes in pregnancy (e.g., increased clearance, volume of distribution) are not relevant as drug is not used.
Not applicable; combination hormonal contraceptives are contraindicated in pregnancy. No dose adjustments are recommended or studied. Discontinue immediately upon pregnancy diagnosis. Alternative contraception should be used if needed.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,The first 21 pills contain hormones; the last 7 are placebo (reminder pills) and a period will occur during that week.,If you miss a pill, refer to the package insert; if you miss two or more, use a backup method like condoms for 7 days.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve after 2-3 cycles.,Contact your healthcare provider if you experience severe leg pain, chest pain, sudden shortness of breath, or severe headache.,This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,If you miss a period, consider pregnancy and take a pregnancy test before starting the next pack.
Take one pill daily at the same time; missing pills increases pregnancy risk.,You will have a period only once every 3 months (during the last week of each cycle).,Use backup contraception if you miss 2 or more active pills in a row.,Common side effects include spotting, nausea, breast tenderness, and mood changes.,Do not smoke while taking this medication, especially if over 35.,This does not protect against STIs; use condoms for prevention.,Inform your doctor if you have migraines, high blood pressure, or a history of blood clots.